DK156779A - Fremgangsmaade til fremstilling af cycloalkyltriazoler - Google Patents

Fremgangsmaade til fremstilling af cycloalkyltriazoler

Info

Publication number
DK156779A
DK156779A DK156779A DK156779A DK156779A DK 156779 A DK156779 A DK 156779A DK 156779 A DK156779 A DK 156779A DK 156779 A DK156779 A DK 156779A DK 156779 A DK156779 A DK 156779A
Authority
DK
Denmark
Prior art keywords
cycloalkyltriazoles
procedure
preparation
Prior art date
Application number
DK156779A
Other languages
English (en)
Other versions
DK148480B (da
DK148480C (da
Inventor
B Silvestrini
L Baiocchi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of DK156779A publication Critical patent/DK156779A/da
Publication of DK148480B publication Critical patent/DK148480B/da
Application granted granted Critical
Publication of DK148480C publication Critical patent/DK148480C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
DK156779A 1978-04-18 1979-04-17 Analogifremgangsmaade til fremstilling af cycloalkyltriazoler DK148480C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2242178 1978-04-18
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli

Publications (3)

Publication Number Publication Date
DK156779A true DK156779A (da) 1979-10-19
DK148480B DK148480B (da) 1985-07-15
DK148480C DK148480C (da) 1985-12-16

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
DK156779A DK148480C (da) 1978-04-18 1979-04-17 Analogifremgangsmaade til fremstilling af cycloalkyltriazoler

Country Status (22)

Country Link
US (2) US4252721A (da)
JP (1) JPS5817757B2 (da)
AT (1) AT374477B (da)
AU (1) AU520788B2 (da)
BG (2) BG40654A3 (da)
CA (1) CA1104567A (da)
CH (1) CH639847A5 (da)
DE (1) DE2915318A1 (da)
DK (1) DK148480C (da)
FI (1) FI66378C (da)
FR (1) FR2423221A1 (da)
GB (1) GB2020269B (da)
HU (1) HU179917B (da)
IE (1) IE47965B1 (da)
IL (1) IL56926A (da)
IT (1) IT1094076B (da)
NL (1) NL186635C (da)
PL (1) PL116103B1 (da)
PT (1) PT69502A (da)
SE (1) SE437663B (da)
SU (1) SU852174A3 (da)
YU (1) YU41338B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
WO2000018391A1 (fr) 1998-09-30 2000-04-06 Takeda Chemical Industries, Ltd. Medicaments qui ameliorent le pouvoir de vidange de la vessie
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
CN1302810C (zh) * 2001-07-02 2007-03-07 参天制药株式会社 含α1受体阻断剂作为活性成分的视神经保护药物
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
RS20050106A (en) 2002-08-19 2007-11-15 Pfizer Products Inc., Combination therapy for hyperproliferative diseases
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
UA82698C2 (uk) * 2003-05-30 2008-05-12 Ранбакси Лабораториз Лимитед Заміщені похідні піролу та їх використання в якості інгібіторів hmg-co
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20080214622A1 (en) * 2005-03-21 2008-09-04 Alan Daniel Brown Substituted Triazole Derivatives As Oxytocin Antagonists
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
CL2007002044A1 (es) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112021007725A2 (pt) 2018-10-26 2021-07-27 Ocuphire Pharma, Inc. métodos e composições para tratamento de presbiopia, midríase e outros distúrbios oculares
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (da) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
FR2423221A1 (fr) 1979-11-16
SE7903327L (sv) 1979-10-19
FI66378C (fi) 1984-10-10
IE47965B1 (en) 1984-08-08
FI791217A (fi) 1979-10-19
NL7902489A (nl) 1979-10-22
SE437663B (sv) 1985-03-11
IL56926A0 (en) 1979-05-31
ATA292479A (de) 1983-09-15
SU852174A3 (ru) 1981-07-30
BG40654A3 (en) 1987-01-15
AU4583279A (en) 1979-10-25
IL56926A (en) 1983-09-30
NL186635C (nl) 1991-01-16
CH639847A5 (it) 1983-12-15
PL214969A1 (da) 1980-03-10
AT374477B (de) 1984-04-25
HU179917B (en) 1983-01-28
PL116103B1 (en) 1981-05-30
FR2423221B1 (da) 1983-03-18
US4252721A (en) 1981-02-24
DK148480B (da) 1985-07-15
PT69502A (en) 1979-05-01
YU41338B (en) 1987-02-28
YU86279A (en) 1983-12-31
AU520788B2 (en) 1982-02-25
IT1094076B (it) 1985-07-26
GB2020269B (en) 1982-06-03
IE790646L (en) 1979-10-18
BG61367B2 (bg) 1997-06-30
FI66378B (fi) 1984-06-29
US4307095A (en) 1981-12-22
GB2020269A (en) 1979-11-14
CA1104567A (en) 1981-07-07
JPS54157576A (en) 1979-12-12
IT7822421A0 (it) 1978-04-18
DE2915318A1 (de) 1979-10-31
JPS5817757B2 (ja) 1983-04-09
DE2915318C2 (da) 1990-12-13
DK148480C (da) 1985-12-16
NL186635B (nl) 1990-08-16

Similar Documents

Publication Publication Date Title
DK325079A (da) Fremgangsmaade til fremstilling af tiazolidinderivater
DK365079A (da) Fremgangsmaade til fremstilling af 1-alfa-hydroxylerede calciferoler
DK156779A (da) Fremgangsmaade til fremstilling af cycloalkyltriazoler
DK129879A (da) Fremgangsmaade til fremstilling af n-heterocyclyl-4-piperidinaminer
DK68179A (da) Fremgangsmaade til fremstilling af 9-aminodibenzoepyraner
DK266479A (da) Fremgangsmaade til fremstilling af 3-aminopropoxyarylderivater
DK303079A (da) Fremgangsmaade til fremstilling af imidazolderivater
DK268579A (da) Fremgangsmaade til fremstilling af phenetamolaminer
DK77479A (da) Fremgangsmaade til fremstilling af penicilliner
DK318079A (da) Fremgangsmaade til fremstilling af piperidinforbindelser
DK307279A (da) Fremgangsmaade til fremstilling af phenolethere
DK186179A (da) Fremgangsmaade til fremstilling af carbapenemderivater
DK69479A (da) Fremgangsmaade til fremstilling af 2-phenylimino-imidazolidiner
DK265779A (da) Fremgangsmaade til fremstilling af o-methallyloxyphenol
DK415379A (da) Fremgangsmaade til fremstilling af chromanolderivater
DK433779A (da) Fremgangsmaade til fremstilling af phenylquinolizidiner
DK150471C (da) Fremgangsmaade til fremstilling af trifluormethylphenoler
DK543079A (da) Fremgangsmaade til fremstilling af benzaldehyder
DK58579A (da) Fremgangsmaade til fremstilling af hydroxyphenylethere
DK145179A (da) Fremgangsmaade til fremstilling af 4-methyl-5-hydroxymethyl-imidazol
DK282379A (da) Fremgangsmaade til fremstilling af phenylpiperidinderivater isaer substituerede eventuelt enkeltmaettede 1-benzylphenylpiperidiner
DK160281C (da) Fremgangsmaade til fremstilling af steroid-s-thioesterderivater
DK185179A (da) Fremgangsmaade til fremstilling af 3-halogen-2-hydroxyalkyltrialkylammoniumunchlorider
DK486079A (da) Fremgangsmaade til fremstilling af dihydroxysteroider
DK239279A (da) Fremgangsmaade til fremstilling af 2-oximinophenylacetonitril

Legal Events

Date Code Title Description
PBP Patent lapsed
PBP Patent lapsed